HE vs. HPP: What's the Difference?
At a Glance
Hereditary Pyropoikilocytosis (HPP) is a severe, rare subtype of Hereditary Elliptocytosis (HE). While mild HE involves one mutated gene and is often asymptomatic, HPP involves inheriting two genetic changes, leading to highly fragile red blood cells and severe anemia that usually begins in infancy.
In this answer
3 sections
Hereditary Pyropoikilocytosis (HPP, pronounced pie-row-poy-kill-oh-sigh-TOE-sis) is a rare, severe subtype of Hereditary Elliptocytosis (HE). The main difference between the two lies in their genetics: mild HE typically occurs when a person inherits one mutated gene (autosomal dominant inheritance), while HPP happens when a person inherits two related genetic changes (autosomal recessive inheritance) [1][2]. This double inheritance in HPP leads to extremely fragile red blood cells and severe anemia that usually begins in infancy, whereas mild HE features intact, oval-shaped cells and often causes no symptoms at all [1][3][4].
The Genetic Difference: One Gene vs. Two
To understand HPP, it helps to look at how red blood cell disorders are passed down through families.
Mild Hereditary Elliptocytosis is usually heterozygous, meaning a person has one normal gene and one mutated gene (often involving the SPTA1, SPTB, or EPB41 genes) [1][2]. Because they still have one working gene, their red blood cells produce enough structural protein to remain mostly stable.
HPP, however, is a recessive or compound heterozygous condition, meaning the patient inherited a genetic defect from both parents [1][3]. Most commonly, this involves inheriting a structural mutation from one parent and a specific low-expression gene variant (known as the alpha-LELY allele) from the other [3][5]. On its own, the alpha-LELY variant is harmless. However, when paired with an HE mutation, it drastically reduces the amount of normal structural protein the body can produce, leading to the severe symptoms of HPP [3][6].
Physical Differences in the Blood Cells
These genetic differences directly affect the “skeleton” of the red blood cell, changing how the cells look and behave:
- Mild HE: The red blood cells are shaped like ellipses or cigars (elliptocytes) but are strong enough to circulate through the body and survive a normal lifespan [1][7].
- HPP: The membrane skeleton is profoundly unstable. Under a microscope, the blood cells look highly fragmented (schistocytes, pronounced shis-toe-sites) and unusually small (microspherocytes) [3][8]. A unique hallmark of HPP is thermal sensitivity. Normal red blood cells fragment at very high temperatures (49°C or 120°F), but HPP cells break apart at lower temperatures (45-46°C or 113-114.8°F) [3][8].
- Note on Heat Sensitivity: This is strictly a laboratory test used by pathologists to diagnose the condition. A temperature of 113°F is well above any human body temperature, even during a severe fever. You do not need to worry that summer heat, saunas, hot tubs, or normal childhood fevers will cause your blood cells to break apart.
Symptom Severity: Asymptomatic vs. Severe Anemia
Because HPP cells are so fragile, the clinical experiences of patients are vastly different from those with mild HE:
- Mild HE: The condition is often completely asymptomatic (causing no symptoms). Many people only discover they have it incidentally during routine blood work, and they usually do not require any treatment [4][1].
- HPP: This condition presents as severe hemolytic anemia, meaning the red blood cells are destroyed faster than the body can replace them [9][10]. Symptoms often begin at birth, with infants showing severe jaundice and anemia [9][10].
Managing HPP Long-Term
While HPP can be life-threatening in early infancy and feel overwhelming for parents, the long-term outlook is generally positive with proper care. Over time, some HPP patients’ symptoms may “mellow” into a milder form that resembles typical HE, though the underlying genetic defect remains [9].
Treatment usually focuses on managing the anemia:
- Supportive Care: Doctors often prescribe daily folic acid (folate) supplements to help the body keep up with the rapid production of new red blood cells.
- Blood Transfusions: Regular transfusions may be needed, especially during infancy or times of illness [4][11].
- Splenectomy: In many cases, surgical removal of the spleen (splenectomy) is recommended [4][11]. Because the spleen is responsible for filtering out and destroying the fragile HPP cells, removing it usually significantly improves or resolves the severe anemia, even though the red blood cells will remain abnormally shaped. However, a splenectomy has lifelong implications, including an increased risk of certain infections, which requires ongoing vaccinations and preventive care.
Common questions in this guide
What is the main genetic difference between HE and HPP?
What is the alpha-LELY gene variant?
Do I need to avoid summer heat or hot tubs if I have HPP?
Will I need my spleen removed if I have HPP?
Do HPP symptoms ever improve over time?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Did my blood tests show fragmented cells (schistocytes) or just elliptocytes?
- 2.If I have mild HE, do I also carry the alpha-LELY gene variant?
- 3.Is genetic testing recommended for me or my partner if we are planning to have children, to understand the risk of HPP?
- 4.If a splenectomy is being considered, what are the specific long-term risks, and what vaccination schedule will be required beforehand?
- 5.Should I be taking a daily folic acid supplement to help my body produce new red blood cells?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (11)
- 1
Unravelling the genetic and phenotypic heterogeneity of SPTA1 gene variants in Hereditary Elliptocytosis and Hereditary Pyropoikilocytosis patients using next-generation sequencing.
Anil More T, Kedar P
Gene 2022; (843()):146796 doi:10.1016/j.gene.2022.146796.
PMID: 35961434 - 2
A Novel α-Spectrin Pathogenic Variant in Trans to α-Spectrin LELY Causing Neonatal Jaundice With Hemolytic Anemia From Hereditary Pyropoikilocytosis Coexisting With Gilbert Syndrome.
Suzuki T, Togawa T, Kanno H, et al.
Journal of pediatric hematology/oncology 2021; (43(2)):e250-e254 doi:10.1097/MPH.0000000000001796.
PMID: 32287101 - 3
Red cell ektacytometry in two patients with chronic hemolytic anemia and three new α-spectrin variants.
Vives-Corrons JL, Krishnevskaya E, Hernández-Rodriguez I, et al.
Annals of hematology 2022; (101(3)):549-555 doi:10.1007/s00277-021-04723-5.
PMID: 34845540 - 4
Clinical and molecular genetic analysis of a Chinese family with hereditary elliptocytosis caused by a novel mutation in the EPB41 gene.
Cao M, Huang Z, Zhou H, et al.
Journal of clinical laboratory analysis 2021; (35(6)):e23781 doi:10.1002/jcla.23781.
PMID: 33942936 - 5
Hypophosphatasia: a genetic-based nosology and new insights in genotype-phenotype correlation.
Mornet E, Taillandier A, Domingues C, et al.
European journal of human genetics : EJHG 2021; (29(2)):289-299 doi:10.1038/s41431-020-00732-6.
PMID: 32973344 - 6
Hereditary elliptocytosis-associated alpha-spectrin mutation p.L155dup as a modifier of sickle cell disease severity.
Risinger M, Christakopoulos GE, Schultz CL, et al.
Pediatric blood & cancer 2019; (66(2)):e27531 doi:10.1002/pbc.27531.
PMID: 30393954 - 7
A novel mutation in SPTA1 identified by whole exome sequencing in a Chinese family for hereditary elliptocytosis presenting with hyperbilirubinemia: A case report.
Xi Y, Wang L, Zhang P, et al.
Medicine 2019; (98(22)):e15800 doi:10.1097/MD.0000000000015800.
PMID: 31145309 - 8
Advances in understanding the pathogenesis of red cell membrane disorders.
Iolascon A, Andolfo I, Russo R
British journal of haematology 2019; (187(1)):13-24 doi:10.1111/bjh.16126.
PMID: 31364155 - 9
Homozygous SPTA1-associated hereditary pyropoikilocytosis presenting as hydrops fetalis.
Brancamp R, Hughes CE, Dar A, et al.
Transfusion 2024; (64(1)):189-193 doi:10.1111/trf.17617.
PMID: 38031483 - 10
Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis.
Niss O, Chonat S, Dagaonkar N, et al.
Blood cells, molecules & diseases 2016; (61()):4-9.
PMID: 27667160 - 11
Hereditary Pyropoikilocytosis as a Modifier of Sickle Cell Disease Severity.
Lantz M, Dolatshahi L
Journal of pediatric hematology/oncology 2025; (47(3)):128-130 doi:10.1097/MPH.0000000000003012.
PMID: 40036694
This information is for educational purposes only and does not substitute for professional medical advice. Always consult a hematologist or healthcare provider for an accurate diagnosis and treatment plan for inherited red blood cell disorders.
Get notified when new evidence is published on Hereditary elliptocytosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.